期刊文献+

老年男性2型糖尿病患者血清护骨素水平与骨密度的关系

下载PDF
导出
摘要 目的研究老年男性2型糖尿病患者的血清护骨素水平,并探讨其与骨密度的关系。方法收集老年男性2型糖尿病患者58例和对照组25例,测定血清护骨素水平,同时检测腰椎和左侧股骨近端骨密度。根据骨密度结果将糖尿病患者分为骨量正常组、骨量减低组和骨质疏松组。结果糖尿病组的护骨素水平较对照组升高(P<0.01)。糖尿病三组间的护骨素水平无明显差别。护骨素与年龄呈正相关,与腰椎和股骨近端骨密度无明显相关。结论没有证据显示老年男性2型糖尿病患者的护骨素水平与骨密度有关。
出处 《南方医科大学学报》 CAS CSCD 北大核心 2008年第8期1506-1507,共2页 Journal of Southern Medical University
  • 相关文献

参考文献6

  • 1孙立亮,张伟,李玉坤.护骨素与骨质疏松研究进展[J].河北医科大学学报,2007,28(1):70-72. 被引量:2
  • 2Stem A, Laughlin GA, Bergstrom J, et al. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappa B legend with bone mineral density in older adults: the Rancho Bemardo study[J]. Eur J Endocrinol, 2007, 156 (5): 555-62.
  • 3周燕莉,李婷,金大地.男性老年性骨质疏松症患者血清骨保护素、核因子-кB受体活化子配体的变化及其与骨密度的关系[J].广东医学,2005,26(4):485-486. 被引量:7
  • 4Alvarez L, Peris P, Guanabens N, et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates[J]. Arthritis Rheum, 2003, 48: 824-28.
  • 5Anand DV, Lahiri A, Lim E, et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects [J]. J Am Coll Cardiol, 2006, 47(9): 1850-7.
  • 6Xiang GD, Xu L, Zhao LS, et al. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes[J]. Diabetes, 2006, 55(7): 2126-31.

二级参考文献26

  • 1苏欣,廖二元,彭健,伍贤平.雌二醇对人成骨肉瘤MG63细胞株护骨素、护骨素配体及其相关因子的调节[J].中华内科杂志,2003,42(11):800-803. 被引量:13
  • 2Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor(OCIF) and osteoprotegerin(OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology,1998,139:1329.
  • 3Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.Nature, 1999,397:315.
  • 4Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res, 1999,14:518.
  • 5Tsuda E, Goto M, Moochizuki S, et al. Isolation of a novel cytokine from human fobroblasts that specifically inhibits osteoclastogenesis. BiochemBiophys Res Commun, 1997,234:137.
  • 6Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell,1997;89:.
  • 7Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998,17;93:165.
  • 8Eghbali Fatourechi G,Khosla S,Sanyal A,et al.Role of Rank Ligand in mediating increased bone resorption in early postmenopausal women[J].J Clin invest,2003,111 (8):1120-1122.
  • 9Vidal K,van den Broek P,Lorget F,et al,Osteoprotegerin in Human Milk:A potential role in the regulation of bone metabolism and immune development[J].Pediatr Res,2004,55(6):1001-1008.
  • 10Hong JS,Santolaya-Forgas J,Romerao R,et al.Maternal plasma osteoprotegerin concentration in normal pregnancy[J].Am J Obstet Gynecol,2005,193(3 Pt 2):1011-1015.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部